German health-care company Fresenius SE reported higher adjusted profit and revenues in the first quarter compared to the same period of the previous year, excluding Fresenius Medical Care.
German health-care company Fresenius SE reported higher adjusted profit and revenues in the first quarter compared to the same period of the previous year, excluding Fresenius Medical Care.
Meanwhile, the adjusted earnings before interest and taxes (EBIT) margin was lower than the previous year. Further, the company confirmed its fiscal 2025 outlook.
Adjusted net income, excluding Fresenius Medical Care following the reduction of its stake, was €416 million ($472.5 million), compared to last year’s €371 million.
Earnings per share were €0.74, higher than the prior year’s €0.66.
Group adjusted EBIT was at €654 million, an increase of 4% from last year’s €631 million, on the back of strong operating performance at Kabi.
Group EBIT margin, meanwhile, dropped to 11.6% from 11.9% a year ago.
Group revenue at €5.63 billion increased 7% from €5.28 billion in the prior year. Organic revenue growth was 7% driven by consistent delivery of Fresenius Kabi and a strong performance at Fresenius Helios.
Looking ahead, for fiscal 2025, Fresenius continues to project organic revenue growth of 4% to 6%, and constant currency EBIT growth in the range of 3% to 7%. In fiscal 2024, revenues were €21.53 billion and EBIT was €2.49 billion.
The company still expects Fresenius Kabi to record organic revenue growth in the mid to high-single-digit percentage range and EBIT margin of 16% to 16.5%; and Fresenius Helios to record organic revenue growth in the mid-single-digit percentage range and EBIT margin around 10%.
(dpa)